# Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma

> **NCT03389438** · PHASE2 · TERMINATED · sponsor: **Beijing Huanxing Cancer Hospital** · enrollment: 6 (actual)

## Conditions studied

- Urinary Bladder Neoplasm

## Interventions

- **BIOLOGICAL:** autologous Tcm cells immunotherapy

## Key facts

- **NCT ID:** NCT03389438
- **Lead sponsor:** Beijing Huanxing Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-26
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-10-31
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Shortage of funds.
- **Last updated:** 2021-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03389438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03389438, "Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03389438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*